Press releases - Ypsomed

Ypsomed continues on its path of growth

03/11/2016 - 07:00 Press Releases Ypsomed Group

Burgdorf – The human insulin of Russian pharmaceutical company GEROPHARM will in future be administered with a pen from Ypsomed's ServoPen® platform. This is a further confirmation of Ypsomed's platform strategy in the field of injection systems.

Ypsomed's ServoPen® for the treatment of Parkinson's disease

19/10/2016 - 07:00 Press Releases Ypsomed Group

Burgdorf – Austrian specialist pharmaceutical company, Ever Pharma, now offers the D-mine Pen for the treatment of Parkinson patients with apomorphine. This reusable pen, which is based on the Ypsomed ServoPen platform, facilitates subcutaneous administration with its patient friendly design.

New member joins Executive Management in the Ypsomed Group

26/09/2016 - 07:00 Press Releases Ypsomed Group

Burgdorf – Michael Zaugg will join the Executive Management of the Ypsomed Group in mid-April 2017 and take on the role of Senior Vice President Human Resources. He will succeed Yvonne Müller, who is leaving Ypsomed at her own request.

Ypsomed increases dividends to shareholders for the third time in a row

30/06/2016 - 07:00 Press Releases Ypsomed Group

Burgdorf – The shareholders of Ypsomed Holding AG approved all proposals by the board of directors by a large majority at the regular general meeting held on 29 June 2016. For the past 2015/16 business year, a dividend of CHF 1.00 per share, exempt from withholding tax, will be paid to shareholders from reserves arising from capital contributions.

Ypsomed collaborates with Novo Nordisk to provide new solutions in insulin pump therapy

27/06/2016 - 07:00 Press Releases Ypsomed Group

Burgdorf – To deliver innovative care solutions, that improve the lives of people with diabetes, is the focus of the collaboration between Ypsomed and Novo Nordisk: Ypsomed’s own developed insulin pump mylife YpsoPump is fully compatible with NovoRapid PumpCart by Novo Nordisk.